Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
1 participants
INTERVENTIONAL
2018-09-15
2021-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effects of a Positive Expiratory Pressure (PEP) on Dyspnea and Dynamic Hyperinflation During Exercise in Chronic Obstructive Pulmonary Disease (COPD) Patients
NCT00741832
Comparison of Two Positive Expiratory Pressure Devices in Stable COPD Patients
NCT02817529
A Study of Expiratory Pressure Modulation in Moderate to Severe COPD Patients - Phase 1b
NCT02585752
Effects of Exhalation Valve on the Lack of Air and Exercise Tolerance in Patients With COPD
NCT02566915
Intermittent Intrapulmonary Deflation and Dyspnea Following Exercise in People With Chronic Obstructive Pulmonary Disease
NCT06956742
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
IC will be measured before, during and immediately after the IT session. Each participant will receive perform IT sessions including either the use of a PEP of 10 cmH2O or a PEP of 1 cmH2O. The effects on IC and dyspnea on both PEP levels will be assessed.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm A
In this arm, patients will receive the experimental condition first, then the sham condition
PEP-10
Bottle PEP with a water level of 10 cmH2O
PEP-1
Bottle PEP with a water level of 1 cmH2O
Arm B
In this arm, patients will receive the sham condition first, then the experimental condition
PEP-10
Bottle PEP with a water level of 10 cmH2O
PEP-1
Bottle PEP with a water level of 1 cmH2O
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PEP-10
Bottle PEP with a water level of 10 cmH2O
PEP-1
Bottle PEP with a water level of 1 cmH2O
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Able to understand the instructions
Exclusion Criteria
* In exacerbation
* Orthopedic of neurological condition likely to interfere with the experimentation
* Contraindication to perform exercise
45 Years
95 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
William Poncin, PT, PhD
Principal Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cliniques universitaires Saint-Luc
Brussels, , Belgium
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PEP-IC
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.